As reported by the Wall Street Journal in​ its’ article entitled​ "How Pfizer Set the Cost of its New Drug at​ $9,850," Pfizer determined that:. A. a price below​ $10,000 (or its determined price of​ $9,850) for its new drug Ibrance would result in a rapid increase in its marginal costs.
B. a price below​ $10,000 (or its determined price of​ $9,850) for its new drug Ibrance would result in a decline in its​ (total sale) revenues reflecting a price elasticity greater than one​ (in absolute​ value) for prices less than​ $10,000.
C. a price above​ $10,000 (or its determined price of​ $9,850) for its new drug Ibrance would result in a decline in its​ (total sale) revenues reflecting a price elasticity less than one​ (in absolute​ value) for prices exceeding ​$10,000.
D. a price above​ $10,000 (or its determined price of​ $9,850) for its new drug Ibrance would result in a decline in its​ (total sale) revenues reflecting a price elasticity greater than one​ (in absolute​ value) for prices exceeding ​$10,000.